U.S., Dec. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07288580) titled 'A Clinical Trial of EHT102 Injection in Pediatric Patients With Biallelic hOTOF Mutations' on Dec. 05.
Brief Summary: This study is a multicenter, single-arm, open-label Phase I/II clinical trial, which is designed to evaluate the safety, tolerability and efficacy of EHT102 injection in treating congenital hearing loss secondary to biallelic mutations of OTOF (DFNB9).Up to 30 pediatric participants (A maximum of 15 participants will be enrolled in each of the United States and China) will be enrolled and dosed with EHT102. The dose-escalation phase (Phase I) includes two predefined dose cohorts (3 participants per cohort), with sequ...